Pioneering clinical trials have demonstrated that patients receiving fecal microbiota transplantation (FMT) and ICIs overcame resistance or experienced high clinical response to anti-PD-1 therapy in treating gastrointestinal cancers54 and melanoma.46 This evidence concerns the gene PDCD1 and melanoma.